期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

洛美利嗪衍生物CJZ3对K562/DOX细胞阿霉素耐药的逆转作用 被引量：3

Reversal of resistance to doxorubicin by CJZ3,a lomerizine amlodipine derivative,in doxorubicin-resistant human myelogenous leukemia(K562/DOX) cells
下载PDF
导出
摘要 目的研究洛美利嗪衍生物CJZ3对K562/DOX细胞阿霉素耐药的逆转作用。方法应用流式细胞仪和MTT法观察了CJZ3对K562/DOX细胞P-糖蛋白(P-glycoprotein,P-gp)的抑制作用及对K562/DOX细胞阿霉素耐药的逆转作用。结果CJZ3能剂量相关性地增加K562/DOX细胞对罗丹明123(rhodamine123,Rh123)的摄取以及细胞内罗丹明Rh123的累计,明显抑制P-gp介导的Rh123外排,增强阿霉素对K562/DOX细胞的细胞毒作用,提高阿霉素诱导的K562/DOX细胞凋亡率,提高细胞Caspase-3活性,增加K562/DOX细胞内阿霉素水平。结论洛美利嗪衍生物CJZ3体外能明显抑制P-gp的外排功能,逆转P-gp介导的K562/DOX细胞的多药耐药性。 Aim To investigate the reversal of resistance to doxorubicin by CJZ3,a lomerizine derivative,in doxorubicin-resistant human myelogenous leukemia（K562/DOX）cells.Methods The effect of CJZ3 on P-glycoprotein（P-gp）function and resistance to doxorubicin in K562/DOX cells were observed by using flow cytometry and MTT assay.Results CJZ3 increased intracellular uptake and accumulation of rhodamine123（Rh123）in K562/DOX cells in a concentration-related manner,significantly inhibited the efflux of Rh123 from the cells,and increased the doxorubicin-induced cytotoxicity,apoptosis rate,Caspase-3 activity in doxorubicin-treated cells and the intracellular accumulation of doxorubicin.Conclusions The reversed effect of CJZ3 on resistance to doxorubicin in K562/DOX cells was associated with its inhibitory effect on P-gp function in vitro.
作者 姬汴生 岳淑梅 何玲
机构地区 河南大学药物研究所 中国药科大学药理学教研室
出处 《中国药理学通报》 CAS CSCD 北大核心 2007年第11期1431-1436,共6页 Chinese Pharmacological Bulletin
基金 国家高技术研究发展计划(863计划)资助项目(No2002AA2Z343E) 江苏省自然科学基金资助项目(NoBK2004110)
关键词 CJZ3 P-糖蛋白 多药耐药 阿霉素 逆转作用 CJZ3 P-glycoprotein multidrug resistance doxorubicin reversal
分类号 R329.25 [医药卫生—人体解剖和组织胚胎学] R341.32 [医药卫生—基础医学]
  • 相关文献

参考文献14

  • 1戴春岭,符立梧.肿瘤多药耐药逆转剂的研究进展[J].中国药理学通报,2005,21(5):513-518. 被引量：39
  • 2Gottesman M M,Pastan I.Biochemistry of multidrug resistance mediated by the multidrug transporter[J].Annu Rev Biochem,1993,62:385-427.
  • 3Katoh M,Nakajima M,Yamazaki H,et al.Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport:comparison with the effects on CYP3A4[J].Pharmaceu Res,2000,17(10):1189-97.
  • 4Hansen M B,Nielsen S E,Berg K,et al.Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill[J].J Immuno Methods,1998,119(2):203-10.
  • 5Gong J,Traganos F,Darzynkiewicz Z.A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry[J].Anal Biochem,1994,218(2):314-9.
  • 6Tatu C A,Paunescu V,Stanescu D I,et al.P-glycoprotein mediated multidrug resistance assessment by flow-cytometry in malignant hemopathies[J].Anticancer Res,1997,17(4A):2583-6.
  • 7Ikegawa T,Ohtani H,Koyabu N,et al.Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia(K562/ADM) cells[J].Cancer Letters,2002,177(1):89-93.
  • 8Green L J,Marder P,Slapak C A.Modulation by LY335979 of Pglycoprotein function in multidrug-resistant cell lines and human natural killer cells[J].Biochem Pharmacol,2001,61(11):1393-9.
  • 9Weisburg J H,Curcio M,Caron P C,et al.The multidrug resistance phenotype confers immunological resistance[J].J Exp Med,1996,183(6):2699-704.
  • 10Stennicke H R,Salvesen G S.Biochemical characteristics of Caspase-3,-6,-7and-8[J].J Biol Chem,1997,272(41):25719-23.

二级参考文献25

  • 1Visani G, Milligan D, Leon F et al. Combined action of PSC833(Valspodar),a novel MDR reversing agent,with mitoxantrone,etoposide and cytarabine in poor prognosis acute myeloid leukemia[J].Leukemia, 2001,15(5):764-71.
  • 2Bates S E, Bakke S, Kang M et al. A phase Ⅰ/Ⅱ study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC833) in renal cell carcinoma[J].Clin Cancer Res, 2004,10(14):4724-33.
  • 3Kankesan J, Vanama R, Yusuf A et al. Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats[J].Carcinogenesis,2004,25(3): 425-30.
  • 4Rago RP,Einstein A Jr, Lush R et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer[J].Cancer Chemother Pharmacol, 2003,51(4): 297-305.
  • 5Toppmeyer D, Seidman AD, Pollak M et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel[J].Clin Cancer Res, 2002, 8(3):670-8.
  • 6Minderman H, O'Loughlin KL, Pendyala L et al. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing ultidrug resistance protein, and breast cancer resistance protein[J].Clin Cancer Res,2004,10(5):1826-34.
  • 7Maliepaard M, van Gastelen MA, Tohgo A et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918[J].Clin Cancer Res, 2001,7(4): 935-41.
  • 8Malingre MM, Beijnen JH, Rosing H et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients[J].Br J Cancer, 2001,84(1):42-7.
  • 9Bardelmeijer HA,Beijnen JH,Brouwer KR et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein[J].Clin Cancer Res, 2000,6(11):4416-21.
  • 10Rubin EH, de Alwis DP, Pouliquen I et al. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies[J]. Clin Cancer Res,2002,8(12):3710-7.

共引文献38

同被引文献20

  • 1赵灵芝,银巍,苏兴文,肖茹,曹林,邱鹏新,颜光美.IGF-1经PI3K/Akt依赖性途径保护苯妥英诱导的小脑颗粒神经元凋亡[J].中国药理学通报,2005,21(1):53-57. 被引量：15
  • 2夏曙,于世英.抑制PI3K/Akt信号转导通路提高化疗效果的实验研究[J].肿瘤,2006,26(4):311-313. 被引量：21
  • 3王玲,刘世坤,周于禄,裴奇.华蟾素对人乳腺癌细胞阿霉素多药耐药性的逆转作用[J].中国药理学通报,2007,23(5):677-680. 被引量：38
  • 4Han Z, Hong L, Han Y, et al. Phospho Akt mediates muhidrug resistance of gastric cancer ceils through regulation of P-gp, Bcl-2 and Bax[ J]. J Exp Clin Cancer Res,2007,26( 2 ) :261 -8.
  • 5Misra S,Ghatak S,Toole B P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2 [ J ]. J Biol Chem,2005 ,280 (21) :20310 - 5.
  • 6Michl P, Downward J. Mechanisms of disease:PI3 K/AKT signaling in gastrointestinal cancers [ J ]. J Gastroenterol, 2005,43 ( 10 ) : 1133 -9.
  • 7Nam S Y, Lee H S, Jung G A, et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis [J]. APMIS,2003 ,111(12) :1105 - 13.
  • 8Ghosh S, Karln M. Missing pieces in the NF-kappaB puzzle [ J ]. Cell,2002,109Suppl: S81 - 96.
  • 9Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges [ J ]. Exp Rev Anticancer Ther,2007,7 (10) : 1369 - 78.
  • 10Ambudkar, Suresh V, Kimchi-Sarfaty C, et al. P-glycoprotein: from genomics to mechanism [ J ]. Oncogene, 2003,22 ( 47 ) : 7468 - 85.

引证文献3

二级引证文献18

中国药理学通报
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部